Bigfoot Biomedical

Bigfoot Biomedical is a US-based company dedicated to diabetes management, founded by individuals with personal ties to Type 1 and Type 2 diabetes. The company aims to enhance diabetes care through a holistic approach to insulin therapy, focusing on integrated services and support for those often overlooked by traditional diabetes innovations. The flagship product, the Bigfoot Unity Diabetes Management System, offers real-time insulin dose recommendations by integrating data from continuous glucose monitors and healthcare professional instructions. Key features include real-time hypoglycemia alerts through the FreeStyle Libre 2 sensor and support for individuals who require multiple daily insulin injections. In 2023, Abbott acquired Bigfoot Biomedical, furthering its commitment to personalized and connected diabetes solutions.